Analyst Ratings For NASDAQ:SMMT – Summit Therapeutics (NASDAQ:SMMT)
Today, Janney Montgomery Scott initiated coverage on NASDAQ:SMMT – Summit Therapeutics (NASDAQ:SMMT) with a Buy with a price target of $27.00.
Some recent analyst ratings include
- 5/2/2018-Janney Montgomery Scott initiated coverage with a Buy rating.
- 2/13/2018-BTIG Research initiated coverage with a Buy rating.
- 1/4/2018-SunTrust Banks initiated coverage with a Buy rating.
- 10/16/2017-Canaccord Genuity Reiterated Rating of Buy.
Recent Trading Activity for NASDAQ:SMMT – Summit Therapeutics (NASDAQ:SMMT)
Shares of NASDAQ:SMMT – Summit Therapeutics closed the previous trading session at 13.49 up +0.31 2.35% with 13.5 shares trading hands.